Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Skyward Specialty Insurance Group has flipped the script from last week: the stock is up nearly 9% over the past five days, short sellers are trimming, and options traders have moved sharply into call territory, a clean reversal of the pattern that defined the September note.
The change in short positioning is the most notable shift since the previous article. Short interest has fallen 3.4% over the past week to 5.0% of the free float, reversing a portion of the month-long rebuild that peaked near 5.2%. The ORTEX short score has eased slightly, from around 42.5 at the start of the week to 41.8 by October 7, a modest drift lower rather than a sharp unwind. The borrow market tells the same relaxed story it has all autumn: availability remains above 2,100% of short interest, meaning there are more than twenty shares available for every one currently lent out. Cost to borrow is 0.49%, up about 11% on the week but still firmly in the negligible range. Shorts are retreating, not being squeezed out.
Options positioning has shifted more dramatically. The put/call ratio has dropped to 0.28, nearly two standard deviations below its 20-day average of 0.44. That places it at roughly the lowest level of the past year, with the 52-week floor at 0.27. A ratio this low reflects heavy call-side activity relative to puts. Whether that is driven by fresh bullish conviction or short-term speculation on the week's bounce is hard to distinguish from the ratio alone, but the contrast with the more cautious stance seen through late September is stark.
The Street remains constructive, though the most recent analyst actions are from August and therefore reflect the Q2 print rather than any fresh catalyst. Following the August 5 earnings beat, multiple firms lifted targets: Keefe Bruyette raised to $75, Truist to $75, and Barclays to $68, all maintaining existing positive ratings. TD Cowen kept its Hold but moved its target sharply from $49 to $65. The consensus price target is $70.45, implying about 23% above the current price of $57.47. At a trailing PE of around 10.6x and price-to-book near 1.76x, the stock is not expensively priced on those metrics. Factor scores are middling: EPS momentum over 30 and 90 days sits near the 50th percentile, the short-score rank is in the 30th percentile, and the dividend score is low at 16, consistent with a company ploughing capital back into growth.
Institutional ownership adds a layer of support to the picture. BlackRock holds 8.3% of shares as of September 30, adding around 349,000 shares in the most recent reported period. T. Rowe Price holds 6.1% and added a substantial 685,000 shares over the same window. Invesco crossed the 5% threshold in August and also filed a 13G. None of the five 13D/G filers on the register have filed as an activist: all five carry Schedule 13G designations, indicating passive intent. As the disclosure note on those filings states, stakes are as-last-disclosed around the 5% threshold, and a holder can drop below 5% without filing again.
Retail attention is also elevated. The ORTEX alt-data mover for Wikipedia page views shows a z-score of 3.88 against the stock's own 90-day history, the highest reading in the dataset window. That is an attention signal rather than a fundamental one, but it does suggest the stock is drawing more eyes than usual, consistent with the week's price move.
Earnings arrive on November 5, four weeks away. The past four quarterly prints have all produced positive next-day moves, ranging from 1.7% to 6.6%, though the five-day reaction has been more mixed. With SI at 5% and call positioning unusually dominant, what happens to both of those positions in the run-up to the print is the main thing worth tracking.
See the live data behind this article on ORTEX.
Open SKWD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
